LONDON and MILAN, Jan. 08, 2026 (GLOBE NEWSWIRE) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026 in San Francisco, California. AAVantgarde's CEO, Dr. Natalia Misciattelli, will provide a corporate […]
(NasdaqGM:SGMT), SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster
DUBAI, United Arab Emirates, Jan. 08, 2026 (GLOBE NEWSWIRE) — In Crypto Market, the projects that tend to break out are not always the loudest ones. They are the ones that keep shipping, keep tightening the product, and keep pulling in participation while the wider market is still looking elsewhere. That is the lane Mutuum
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare mitochondrial disease MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The study enrolled 43 participants, and
Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara's eligibility for milestone payments under existing collaboration Scott Drutman, M.D., Ph.D. appointed as Chief Medical Officer, adding deep expertise in translational medicine, extensive earlyâ€'stage clinical trial execution, and proven immunoâ€'oncology drug development experience Enara's ENA101, a bispecific
(OTCQB:ACUT),(OTC US:ACUT), PHOENIX, Jan. 08, 2026 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a subset of patients from the B-32 cohort. This
Combination of AT7687 and cagrilintide demonstrated enhanced weight loss effect in obese, insulin-resistant, pre-diabetic non-human primate (NHP) model Additional weight loss observed in combination group was independent of appetite suppression Combination synergistically boosted insulin sensitivity and improved body composition, reducing fat mass rather than lean mass Positive data builds on previously demonstrated results showing additive
CMR Surgical receives CE Mark for use of Versius in paediatric surgery Small, modular design of the Versius system supports use in robotic-assisted paediatric surgery Cambridge, UK – 8 January 2026, CMR Surgical ('CMR' or 'the Company'), the global surgical robotics business, today announces that it has received CE and UKCA Marks for its Versius
(NASDAQ:INDV), Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE(R) Net Revenue Expected to be in the Range of $905 million to $945 million Non-GAAP Operating Expenses Expected in the Range of $430 million to $450 million Adjusted EBITDA Expected in the Range of $535 million to $575 million
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference GlobeNewswire January 08, 2026 NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided